Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial

S. Ramakrishnan (Oxford, United Kingdom), D. Nicolau Jr (Oxford, United Kingdom), B. Langford (Oxford, United Kingdom), M. Mahdi (Oxford, United Kingdom), H. Jeffers (Oxford, United Kingdom), C. Mwasuku (Oxford, United Kingdom), K. Krassowska (Oxford, United Kingdom), R. Fox (Bicester, United Kingdom), I. Binnian (Eynsham, United Kingdom), V. Glover (Faringdon, United Kingdom), S. Bright (Witney, United Kingdom), C. Butler (Oxford, United Kingdom), J. Cane (Oxford, United Kingdom), A. Halner (Oxford, United Kingdom), P. Matthews (Oxford, United Kingdom), L. Donnelly (London, United Kingdom), J. Simpson (Newcastle, New South Wales, Australia), J. Baker (London, United Kingdom), N. Fadai (Nottingham, United Kingdom), S. Peterson (Lund, Sweden), T. Bengtsson (Lund, Sweden), P. Barnes (London, United Kingdom), R. Russell (Oxford, United Kingdom), M. Bafadhel (Oxford, United Kingdom)

Source: Virtual Congress 2021 – ALERT: bronchiectasis and COVID
Session: ALERT: bronchiectasis and COVID
Session type: Clinical trials session
Number: 4270

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Ramakrishnan (Oxford, United Kingdom), D. Nicolau Jr (Oxford, United Kingdom), B. Langford (Oxford, United Kingdom), M. Mahdi (Oxford, United Kingdom), H. Jeffers (Oxford, United Kingdom), C. Mwasuku (Oxford, United Kingdom), K. Krassowska (Oxford, United Kingdom), R. Fox (Bicester, United Kingdom), I. Binnian (Eynsham, United Kingdom), V. Glover (Faringdon, United Kingdom), S. Bright (Witney, United Kingdom), C. Butler (Oxford, United Kingdom), J. Cane (Oxford, United Kingdom), A. Halner (Oxford, United Kingdom), P. Matthews (Oxford, United Kingdom), L. Donnelly (London, United Kingdom), J. Simpson (Newcastle, New South Wales, Australia), J. Baker (London, United Kingdom), N. Fadai (Nottingham, United Kingdom), S. Peterson (Lund, Sweden), T. Bengtsson (Lund, Sweden), P. Barnes (London, United Kingdom), R. Russell (Oxford, United Kingdom), M. Bafadhel (Oxford, United Kingdom). Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial. 4270

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Omalizumab in patients with moderate-to-severe persistent asthma poorly controlled on high-dose inhaled corticosteroids and long-acting beta-agonists: Results of a phase IIIb randomized controlled trial
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010


Clinical effectiveness of MDI-HFA-Modulite budesonide in the treatment of asthma – meta-analysis of randomised controlled trials
Source: Eur Respir J 2006; 28: Suppl. 50, 315s
Year: 2006

Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT?
Source: ERJ Open Res 2016: 00055-2016
Year: 2016



Budesonide versus prednisone in acute wheezing: randomized double-blinded controlled placebo study
Source: Annual Congress 2008 - Treatment and outcome of childhood asthma: new perspectives
Year: 2008


Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial
Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021
Year: 2021



Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial
Source: Eur Respir J, 58 (1) 2100130; 10.1183/13993003.00130-2021
Year: 2021



Clinical effectiveness of MDI-HFA-Modulite beclomethasone in the treatment of asthma – meta-analysis of randomized controlled trials
Source: Eur Respir J 2006; 28: Suppl. 50, 315s
Year: 2006

Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma
Source: Eur Respir J 2016; 47: 981-984
Year: 2016


A multi-centre doubleblind randomised study examining the clinical outcome of treatment of the first asthma exacerbation with salmeterol xinafoate/fluticasone propionate combination product versus prednisolone
Source: Eur Respir J 2003; 22: Suppl. 45, 287s
Year: 2003

A randomised controlled trial of zafirlukast in acute asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 254s
Year: 2005

Randomized controlled trial of nebulized budesonide suspension in acute severe exacerbation of COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 244s
Year: 2002

Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial.
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018


Airway hyperresponsiveness to mannitol as a predictor of treatment response to ciclesonide in patients with suspected asthma: A double-blind, randomised, placebo-controlled trial
Source: Annual Congress 2012 - Bronchial challenge as a biomarker of respiratory disease
Year: 2012

Efficacy and safety of as-needed corticosteroid plus fast or short-acting beta-agonists monotherapy in patients with mild asthma: a meta-analysis of randomised controlled trials.
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020

The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCS randomised controlled trial
Source: Eur Respir J, 57 (6) 2003338; 10.1183/13993003.03338-2020
Year: 2021



Late Breaking Abstract - The impact of regular bisoprolol on recovery with salbutamol in asthma; a double-blind randomised controlled trial
Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies
Year: 2019


Double-blind placebo controlled randomized trial of montelukast in acute RSV bronchiolitis
Source: Annual Congress 2007 - Bronchiolitis - viruses, treatment and outcome
Year: 2007


A phase-III multicenter, randomized, double-blind, controlled trial of high-dose inhaled nitric oxide in infants with acute bronchiolitis.
Source: International Congress 2018 – Paediatric respiratory infections: mechanistic insights and clinical outcomes
Year: 2018